

WE HAVE APPLIED FOR EACCME POINTS!
RECOGNIZED BY ALL LOCAL CERTIFICATION BODIES!



VACCELERATE has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101037867.



MARCH 23 2022 15:00 (CET)

Webinar:

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study

With Prof. Manoel Barral-Netto, LIB and LEITV Laboratories, Instituto Goncalo Moniz, Fiocruz, Salvador & Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil

Aging influences COVID-19 severity and response to vaccination, but previous vaccine effectiveness analyzes lack the power to evaluate its role in subgroups within the elderly age group.

Prof. Barral-Netto and his team analyzed the impact of age on viral vector and inactivated virus vaccines' effectiveness, the main platforms used in low- and middle-income countries.

They report a retrospective longitudinal study of nearly 76 million Brazilian vaccinees from January 18 to July 24, 2021, evaluating documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19-related hospitalization, ICU admission, and death.

In this webinar, Prof. Barral-Netto reports if the tested vaccines have been effective in protecting against infection, hospitalization and death and how vaccine effectiveness varies in different age groups. He will also include other aspects such as waning, the impact of variants and tell if he recommends further booster vaccination in elders.

VACCELERATE, the EU funded clinical research network for the coordination & conduct of COVID-19 vaccine trials is looking forward to hosting this webinar.

The webinar will be recorded and published on <https://vaccelerate.eu/>.

In cooperation



UNIKLINIK
KÖLN

with



Ministério da Saúde

FIOCRUZ

Fundação Oswaldo Cruz

Webinar:

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines

Presented by

Prof. Manoel Barral-Netto

Moderated by

VACCELERATE

Limited participation for
up to **1.000 persons**

Presentation approx. 1
hour including Q & As

Registration:

webinar.idinmotion.de